This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Evaluating the phase 1b clinical trial data of ziftomenib in patients with AML recently released at EHA 2023.
Ticker(s): KURAWho's the expert?
Institution: Vanderbilt University
- Hematologist and oncologist with Vanderbilt University Medicine
- Currently manages 5 patients with AML
Interview Goalto discuss the standard of care and the potential of ziftomenib, a menin inhibitor being developed by Kura Oncology for the treatment of relapsed or refractory NPM1-mutated AML.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
